Dr. McLaughlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
PO Box 301407
Unit 1671
Houston, TX 77230Phone+1 713-745-9700Fax+1 713-745-1686- Is this information wrong?
Education & Training
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1978 - 1979
- University of ConnecticutResidency, Internal Medicine, 1974 - 1977
- Tufts University School of MedicineClass of 1974
Certifications & Licensure
- TX State Medical License 1980 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Start of enrollment: 1993 Jun 01
- Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
- Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) Start of enrollment: 2003 Feb 01
Publications & Presentations
PubMed
- 6 citationsRituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.P McLaughlin, A J Grillo-López, B K Link, R Levy, M S Czuczman, M E Williams, M R Heyman, I Bence-Bruckler, C A White, F Cabanillas, V Jain, A D Ho, J Lister, K Wey, D...> ;Journal of Clinical Oncology. 2023 Jan 10
- 2 citationsInitial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follic...Felipe Samaniego, Peter McLaughlin, Sattva S. Neelapu, Lei Feng, Michelle A. Fanale, Loretta J. Nastoupil, Maria Alma Rodriguez, Barbara Pro, Erin Taylor, Fredrick B. ...> ;Leukemia & Lymphoma. 2021 Jan 2
- 5 citationsLong-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.Tamer Khashab, Fredrick B. Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Barbara Pro, Peter McLaughlin, M. Alma Rodriguez, Sattva S. Neelapu, Luis Fayad, Anas Y...> ;British Journal of Haematology. 2019 May 1
- Join now to see all
Journal Articles
- Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin LymphomaPeter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: